MAP3K13 and metastatic neoplasm: K252a was selected because it was a prototypical drug which had been modified to give further MLK inhibitor and the new inhibitor URMC-099 was chosen for its distinct chemical structure from K252a and the ability to cross blood-brain barrier which may be promising to treat metastatic tumour.